Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 9c, beats revenue

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($0.92), $0.09 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $3.82 million versus the consensus estimate of $928.57 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Lennar Corp. (LEN) Misses Q2 EPS by 1c